AgingResearch.NewsJoin free

Hexarelin + growth hormone-releasing hormone

Hexarelin + growth hormone-releasing hormone has been studied in 1 paper since 1998: 1 trial in people. The newest paper, Apr 1, 1998: “Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging”.

Intervention

1 paper studies it1 findingUpdated

“In Y the GH response to HEX + GHRH was synergistical (4259.2 +/- 308.0 micrograms/L/h, p < 0.05).”
Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human agingPituitary1998doi:10.1023/a:1009970909015

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Human trial1

What did studies of Hexarelin + growth hormone-releasing hormone find?

1

Studies of Hexarelin + growth hormone-releasing hormone measured 1 outcome; the most studied are GH secretion (1 study).

GH secretion

upin humans1

1 study

  1. Hexarelin + growth hormone-releasing hormone increases GH secretion in humans (Synergistic GH response: 4259.2 ± 308.0 micrograms/L/h).

    “In Y the GH response to HEX + GHRH was synergistical (4259.2 +/- 308.0 micrograms/L/h, p < 0.05).”

    Human trialCombined hexarelin and growth hormone-releasing hormone2.0 micrograms/kg eachn = 12

    Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging

    Pituitary

More on GH secretion

Latest

Related